SCHEDULE F(Form 990)
Department of the Treasury
Internal Revenue Service
Statement of Activities Outside the United States
Right pointing arrow large image Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16.Right pointing arrow large image Attach to Form 990.Right pointing arrow large image Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2020
Open to Public Inspection
Name of the organization
CYSTIC FIBROSIS FOUNDATION
 
Employer identification number

13-1930701
Part I
General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.
1
For grantmakers. Does the organization maintain records to substantiate the amount of its grants and
other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used
to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .
2
For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.
3
Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)
(a) Region (b) Number of offices in the region (c) Number of employees, agents, and independent contractors in the region (d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region) (e) If activity listed in (d) is a program service, describe specific type of
service(s) in the region		 (f) Total expenditures
for and investments
in the region
EUROPE 0 0 GRANTMAKING NONE 7,037,347
EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING NONE 3,736,260
NORTH AMERICA 0 0 GRANTMAKING NONE 2,808,976
MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING NONE 134,109
SUB-SAHARAN AFRICA 0 0 GRANTMAKING NONE 121,744
CENTRAL AMERICA & CARIBBEAN 0 0 INVESTMENTS   1,126,602,000
EAST ASIA & PACIFIC 0 0 INVESTMENTS   235,221,000
EUROPE 0 0 INVESTMENTS   226,768,000
NORTH AMERICA 0 0 INVESTMENTS   59,338,000
MIDDLE EAST AND NORTH AFRICA 0 0 INVESTMENTS   1,552,000
NORTH AMERICA 0 0 PROGRAM SERVICES CONTRACTED RESEARCH 2,949,236
EUROPE 0 0 PROGRAM SERVICES CONTRACTED RESEARCH 1,274,275
EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES CONTRACTED RESEARCH 100,000
           
           
           
           
3a Sub-total .... 0 0 1,602,429,436
b Total from continuation sheets to Part I ... 0 0 65,213,511
c Totals (add lines 3a and 3b) 0 0 1,667,642,947
For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2020
Schedule F (Form 990) 2020
Page 2
Part II
Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.
1 (a) Name of organization (b) IRS code section
and EIN (if applicable)		 (c) Region (d) Purpose of
grant 		(e) Amount of
cash grant 		(f) Manner of
cash
disbursement 		(g) Amount
of noncash
assistance 		(h) Description
of noncash
assistance 		(i) Method of
valuation
(book, FMV,
appraisal, other)
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 130,151 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL RESEARCH STUDY 635,853 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CLINICAL RESEARCH CENTER 984,767 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM QUALITY IMPROVEMENT 1,457,636 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPEUTICS DISCOVERY RESEARCH 136,473 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CLINICAL RESEARCH 182,714 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 132,167 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CLINICAL RESEARCH CENTER 1,021,205 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 54,000 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 16,076 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 275,000 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 134,600 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPEUTICS DISCOVERY RESEARCH 78,560 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 132,300 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES RESEARCH 140,000 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 55,996 WIRE 0    
MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, CLINICAL RESEARCH 52,920 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CLINICAL RESEARCH 757,107 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 135,000 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL RESEARCH STUDY 230,574 WIRE 0    
MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, CLINICAL RESEARCH 81,189 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL RESEARCH CENTER 148,245 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL RESEARCH STUDY 452,627 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES RESEARCH 139,946 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES THERAPEUTICS DISCOVERY RESEARCH 133,000 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 105,911 WIRE 0    
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, RESEARCH 32,357 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 53,999 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES PILOT STUDY 54,000 WIRE 0    
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CLINICAL RESEARCH STUDY 694,490 WIRE 0    
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CLINICAL RESEARCH 654,385 WIRE 0    
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CLINICAL RESEARCH STUDY 1,686,067 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 108,000 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 129,425 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 139,715 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL CARE RESEARCH 145,600 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES PILOT STUDY 54,000 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES THERAPEUTICS DISCOVERY RESEARCH 92,500 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPEUTICS DISCOVERY RESEARCH 202,230 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CLINICAL RESEARCH STUDY 443,397 WIRE 0    
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES RESEARCH 139,234 WIRE 0    
SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, CLINICAL RESEARCH 121,744 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 83,350 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THERAPEUTICS DISCOVERY RESEARCH 428,903 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 49,950 WIRE 0    
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CLINICAL RESEARCH 668,961 WIRE 0    
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PILOT STUDY 52,112 WIRE 0    
2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......MediumBullet
35
3 Enter total number of other organizations or entities .......................MediumBullet
 
Schedule F (Form 990) 2020
Schedule F (Form 990) 2020Page 3
Part III
Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.
(a) Type of grant or assistance (b) Region (c) Number of recipients (d) Amount of
cash grant 		(e) Manner of cash
disbursement 		(f) Amount of
noncash
assistance 		(g) Description
of noncash
assistance 		(h) Method of
valuation
(book, FMV,
appraisal, other)
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Schedule F (Form 990) 2020
Schedule F (Form 990) 2020
Page 4
Part IV
Foreign Forms
1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .
3 Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .
5 Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule F (Form 990) 2020
Schedule F (Form 990) 2020
Page 5
Part V
Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.
ReturnReference Explanation
PART III ACCOUNTING METHOD:  
SCHEDULE F, PART IV PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE OF THE U.S. THE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANTS AWARDED TO ENTITIES OUTSIDE OF THE UNITED STATES. THE ORGANIZATION FOLLOWS THE U.S. DEPARTMENT OF TREASURY ANTI-TERRORIST FINANCING VOLUNTARY BEST PRACTICES GUIDELINES FOR CHARITIES. IN COMPLIANCE WITH THE BEST PRACTICES, THE ORGANIZATION COLLECTS AND REVIEWS INFORMATION ABOUT THE PROSPECTIVE GRANTEES AND CONDUCTS A VETTING PROCESS TO ENSURE THEY ARE NOT SUSPECTED OF ACTIVITIES RELATED TO TERRORISM. ONCE A GRANT IS APPROVED, A WRITTEN AGREEMENT IS SIGNED BY BOTH THE ORGANIZATION AND THE GRANTEE. FUNDING IS INCREMENTAL AND SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE GRANTS TO THE MIDDLE EAST/NORTH AFRICA REGION WERE MADE TO THE RESEARCH FUND OF THE HADASSAH MEDICAL ORGANIZATION AND THE HEBREW UNIVERSITY OF JERUSALEM IN ISRAEL. FOREIGN FORMS THE ACTIVITIES REFERENCED IN SCHEDULE F, PART IV ARE LIMITED TO CERTAIN OF THE FOUNDATION'S INVESTMENTS.
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Schedule F (Form 990) 2020
Additional Data


Software ID:  
Software Version: